Abiopharma

🔍 Dhillon Mannik S. (Executive)

Company: Victory Capital Holdings, Inc. (VCTR)

Report Date: 2026-08-05

Detailed Transactions and Holdings:

• Acquired 16,390 shares of Common Stock (Direct)
  Date: 2026-08-05 | Code: M | equity_swap_involved: false | shares_owned_after: 314,138.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,452 shares of Common Stock at $99.97 per share (Direct)
  Date: 2026-08-05 | Code: F | equity_swap_involved: false | shares_owned_after: 307,686.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 16,390 shares of Performance-based Restricted Stock (Derivative)
  Date: 2026-08-05 | Code: M | equity_swap_involved: false | shares_owned_after: 49,171.00 | transaction_form_type: 4 | Footnotes: F3, F4, F1, F5, F6

Footnotes:

• F1: Acquisition of Common Stock upon settlement of performance-based restricted stock. Each performance-based restricted stock represents a right to receive one share of Common Stock.
• F2: Represents shares of Common Stock withheld to satisfy the reporting person's tax obligation upon the vesting of performance-based restricted stock based on the closing price of the Company's shares on August 5, 2026.
• F3: As disclosed on a Form 8-K filed on March 16, 2026, performance-based shares of restricted stock (the "Performance Shares") were granted to the Reporting Person on March 15, 2026, pursuant to the, Amended and Restated Victory Capital Holdings, Inc. 2018 Equity Plan, with vesting tied to four significant stock price performance hurdles. Each Performance Share represents a contingent right to receive one share of Victory Capital Holdings, Inc., Common Stock.
• F4: Each performance-based restricted stock represents a contingent right to receive one share of Common Stock.
• F5: Performance Shares vested on August 5, 2026 following approval by the Compensation Committee of the Board of Directors of the Issuer of the achievement of the first stock price performance hurdle.
• F6: Not applicable.